Search

Your search keyword '"Ueno, N.T."' showing total 39 results

Search Constraints

Start Over You searched for: Author "Ueno, N.T." Remove constraint Author: "Ueno, N.T." Search Limiters Available in Library Collection Remove constraint Search Limiters: Available in Library Collection
39 results on '"Ueno, N.T."'

Search Results

4. 192MO DESTINY-Breast04 subgroup analyses of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with human epidermal growth factor 2 (HER2)-low, estrogen-receptor (ER) expression immunohistochemistry (IHC) 0-10% metastatic breast cancer (mBC)

5. 185O Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): A detailed safety analysis of the randomized, phase III DESTINY-Breast04 trial

6. Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay

7. 217O Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)

11. Hematopoietic Stem/Progenitor Cells and Engineering: A PHASE 1, FIRST IN HUMAN (FIH) STUDY OF ADENOVIRALLY TRANSDUCED AUTOLOGOUS MACROPHAGES ENGINEERED TO CONTAIN AN ANTI-HER2 CHIMERIC ANTIGEN RECEPTOR (CAR) IN SUBJECTS WITH HER2 OVEREXPRESSING SOLID TUMORS

17. 376O Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study

20. 98O The immunomodulatory (IM) signature enhances prediction of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in triple negative breast cancers (TNBC) with moderate stromal tumour infiltrating lymphocytes (sTIL)

23. Somatic mutations reveal asymmetric cellular dynamics in the early human embryo

24. Somatic mutations reveal asymmetric cellular dynamics in the early human embryo

25. Landscape of somatic mutations in 560 breast cancer whole-genome sequences

26. Landscape of somatic mutations in 560 breast cancer whole-genome sequences

31. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy

32. 280: Serological Evidence of Hepatitis C is Associated with Worse Non-Relapse Mortality and Overall Survival after Allogeneic Stem Cell Transplantation

37. 15 - Hematopoietic Stem/Progenitor Cells and Engineering: A PHASE 1, FIRST IN HUMAN (FIH) STUDY OF ADENOVIRALLY TRANSDUCED AUTOLOGOUS MACROPHAGES ENGINEERED TO CONTAIN AN ANTI-HER2 CHIMERIC ANTIGEN RECEPTOR (CAR) IN SUBJECTS WITH HER2 OVEREXPRESSING SOLID TUMORS

Catalog

Books, media, physical & digital resources